Key facts
- It has raised $28.1M; the latest was Early Stage VC in Nov 2025.
- Notable investors include Suzhou Oriza Holdings Corporation, Lapam Capital, Shanghai Healthcare Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Synvida
- ·The full record, as it builds
Funding rounds
No funding rounds for Synvida are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synvida
Manufacturer of antibody and protein-based therapeutics intended to address unmet needs in fibrosis and coagulation disorders. The company offers proprietary synthetic biology platforms and novel monoclonal antibodies, enabling healthcare providers to advance treatment for patients with pulmonary fibrosis, bleeding disorders, and thrombotic diseases.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2021
- Website
- synvida-bio.com/
- Ownership
- Privately Held (backing)
Synvida doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synvida shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synvida in its N-PORT filings yet. We sweep new filings monthly.